Rattlesnake Bite Research Articles

Characterization of patients with a snakebite presenting to healthcare facilities and reported to poison and drug information centers—Arizona, 2017–2021

Introduction Envenomation after a North American rattlesnake (Crotalus spp. and Sistrusus spp.) bite is associated with substantial morbidity. Arizona reports the highest number of rattlesnake envenomations annually in the United States. We evaluated the performance of poison and drug information centers for snakebite surveillance, compared with the hospital and emergency department discharge database. We used both datasets to improve the characterization of epidemiology, healthcare costs, and clinical effects of snakebite envenomations in Arizona. Methods We identified patients with a snakebite during 2017–2021 using Arizona hospital and emergency department discharge data and snakebite consults with two regional Arizona poison centers. Patients were matched using name and birthdate. The performance of poison center data for snakebite surveillance was evaluated using the percentage of snakebite patients in hospital and emergency department discharge data that consulted with poison centers. Patient demographics, healthcare characteristics, clinical effects, and context of snakebite events were described using both datasets. Results In total, 1,288 patients with a snakebite were identified using the Arizona hospital and emergency department discharge data, which resulted in 953 (74%) consultations with poison centers. The median age of patients was 48 years (IQR 28-62 years), and they were predominantly male (66%), White (90%), and non-Hispanic (84%). The median billed charges were US$ 84,880 (IQR US$ 13,286–US$ 168,043); the median duration of a healthcare stay was 34 h (IQR 13–48 h), and 29% of patients were transferred between healthcare facilities. Among 953 consulted poison center calls for a snakebite, a median of 14 vials of antivenom was administered per patient; 375 (60%) bites occurred near the home, and 345 (43%) patients were bitten on a lower extremity. One death was identified. Discussion Snakebites in Arizona can cause severe morbidity and require extensive healthcare resources for treatment. Poison centers are valuable for monitoring venomous snakebites in Arizona. Conclusions Using hospital and emergency department discharge data with poison center records can improve public health surveillance data regarding snakebite epidemiology and human-snake interaction information and be used to tailor interventions to increase awareness of snake encounters and prevent snakebites.

Evaluation of the International Society on Thrombosis and Haemostasis definition of major bleeding in Arizona rattlesnake bites

Introduction In 2023, a group of experts proposed that a definition of major bleeding in pharmaceutically anticoagulated patients be used in all snakebite trials. This includes bleeding that results in death, is life-threatening, causes chronic sequelae, or consumes major healthcare resources, including bleeding into a major area or hemoglobin concentration decrease ≥20 g/L. We hypothesized that a decline in hemoglobin concentration ≥20 g/L is common but rarely clinically significant in our population of Arizona rattlesnake bite patients. Methods Poison center records of rattlesnake bites in humans from 2018 through 2022 were retrospectively reviewed and assessed for major bleeding by the above criteria. Results Four hundred and eighty-one patients met the inclusion criteria, of whom 265 (55.1%) had a hemoglobin concentration decrease ≥20 g/L. No patients died, and there was no evidence of bleeding into a critical organ. Three patients (1.1%) received blood transfusions. A decrease in hemoglobin concentration ≥20 g/L was 100% sensitive for identifying the major bleeding-associated outcomes; however, specificity was only 45.2%. Measures of healthcare utilization and chronic sequelae were somewhat higher in patients with a decrease in hemoglobin concentration ≥20 g/L. Discussion Laboratory manifestations of hemotoxicity were common in this population, but hemorrhage was rare. While over half of patients met the major bleeding criterion of a decline in hemoglobin concentration ≥20 g/L, only 1.1% had bleeding that was potentially life-threatening as measured by receipt of a red blood cell transfusion. None died or had bleeding into a critical area. While nonspecific for major bleeding, a drop in hemoglobin concentration correlated with worse envenomation severity: these patients received more vials of antivenom, had a higher medical bill, a longer hospital stay, and were less likely to report full recovery at 90 days. Conclusions A decrease in hemoglobin concentration ≥20 g/L should not be used as evidence of major bleeding for Arizona rattlesnake envenomation studies, but it may have a role as an indirect marker of envenomation severity.

Utility of synthetic electrospun fiber matrix in general surgery: From head to toe

BackgroundTo highlight the role of a novel synthetic electrospun fiber matrix in the treatment of high-risk wounds across a range of etiologies. MethodsThis was a retrospective study of patients at a single institution who underwent complex wound care treatment with at least 1 application of the electrospun fiber matrix from January 2021 to December 2022. Information regarding patient demographics, wound size and etiologies, pertinent medical history, and treatment outcomes was collected. ResultsTwenty-one patients with 24 complex wounds who received synthetic electrospun fiber matrix treatment were identified. Nineteen patients (22 wounds) met the inclusion criteria for analysis. Patient mean age was 63.58 ± 15.20 (range 34–90) years. A wide range of wound etiologies was represented, including transmetatarsal amputation secondary to frostbite (n = 1), post-Mohs defect (n = 2), acute trauma (n = 3), surgical dehiscence (n = 3), infected implanted medical device (n = 2), chronic ulcers (n = 3), partial ray resection (n = 1), pilonidal cyst (n = 1), rattlesnake bite (n = 1), necrotizing soft-tissue infection (n = 1), and others (n = 2). A total of 17 of 19 (89.5%) patients were observed to meet their individual clinical goals after application of the wound matrix. Wound ages ranged from 1 to 429 days before initial synthetic electrospun fiber matrix application. ConclusionThe synthetic nature of the matrix limits the risk of inflammatory response and is well tolerated, which demonstrates initial proof of concept of synthetic electrospun fiber matrix treatment in a variety of complex wounds. The positive results observed across this mixed etiology surgical analysis should be replicated in future controlled, single-etiology studies to further confirm the utility of the electrospun fiber matrix in the surgical setting.

Infections following rattlesnake envenomation and use of antibiotics.

There are 7000-8000 venomous snake bites annually in the USA. Antibiotics are commonly administered to bite victims because infection is difficult to differentiate from local tissue injury following envenomation. The Arizona Poison and Drug Information Center (APDIC) in Tucson oversees antivenom administration for 14 Arizona counties. Records (1999-2021) were searched for antibiotic use and confirmed infections after a rattlesnake bite. There were 4160 calls to APDIC regarding rattlesnakes. After excluding bites to animals, 'dry bites', prisoners and records with missing data, 2059 records were evaluated. Systemic antibiotics were administered to 206 patients (10% of bite victims). Twenty patients (0.97%) had confirmed infections, including cellulitis (n=10), fasciitis (n=4), abscess (n=3) and osteomyelitis (n=3). Five of the victims had positive blood cultures. The presence of tissue necrosis, leukocytosis, fever and elevated fibrinogen levels did not discriminate between toxic effects of venom and infection. Confirmed infections following a rattlesnake bite are uncommon (0.97% of bites). Physicians should refrain from prescribing antibiotics, as they are not justified for most rattlesnake bite victims and the variety of pathogens encountered precludes use of any single effective antibiotic.

Delayed Onset of Symptoms After a Rattlesnake Bite in a Renal Transplant Patient: A Case Report.

The United States is home to two major families of venomous snakes, Crotalids and Elapids. The Crotalid family, also known as pit vipers, is well known for being among the most frequent causes of snakebites reported. Crotalid envenomation can present with local findings, hematologic toxicity, and systemic toxicity. Identification of envenomated patients is key to determining who needs antivenom. Most sources recommend an observation period of six to eight hours after the snakebite to determine whether the bite was "dry" or the patient was exposed to venom. We present the case of a 33-year-old patient with a history of renal transplantation who had delayed onset of symptoms of envenomation 18 hours after an initial emergency department observation. The patient did well after a course of antivenom and was discharged on hospital day three. The patient's immunosuppressive regimen may have delayed the onset of clinical symptoms, thus delaying treatment. To the best of our knowledge, this is the first case reported of a patient presenting with a delayed onset of initial snakebite envenomation symptoms.

Geographic variation in the clinical features of Mohave rattlesnake (Crotalus scutulatus) envenomations reported to the North American Snakebite Registry

The geographic variation of Mohave rattlesnake (Crotalus scutulatus) venom is well established. We reviewed all the Mohave rattlesnake bites reported to the Toxicology Investigators Consortium's North American Snakebite Registry between January 1, 2015 and 12/31/2021. Data reviewed for this study included details regarding the snake encounter, patient demographics, signs and symptoms, treatment, and outcomes. Our objective was to describe the epidemiology, clinical manifestations, and management of Mohave rattlesnake envenomations using prospective data from two geographically distinct sites. There were 20 subjects, including eight nonpregnant females. Ages ranged from seven to 75 years, median age 48. Nine of the bites were managed in Arizona and 11 in California. In Arizona, all envenomated patients had local swelling. None had neurological toxicity. In California, swelling was present in nine patients. Neurological effects were observed in five subjects. Four Arizona patients and one California patient had hypotension requiring treatment. Each site had one patient with thrombocytopenia. An Arizona patient who sustained a bite to the face was intubated. Rhabdomyolysis occurred in two California patients. All envenomated patients received antivenom. Mohave rattlesnakes have the potential to cause significant local and/or systemic toxicity. Neurotoxicity was not observed in envenomations from Mohave rattlesnakes that presumably lack Mohave toxin, but hypotension and gastrointestinal signs were more common than in bites from snakes believed to possess Mohave toxin. Neurological toxicity was limited to paresthesias and fasciculations. Significant skeletal or respiratory muscle weakness was not observed in our study population.

Timber rattlesnake (Crotalus horridus): Biology, conservation, and envenomation in the Upper Mississippi River Valley (1982-2020).

The Timber Rattlesnake (Crotalus horridus) is the largest pit viper in the Northern United States and is the prominent venomous snake species indigenous to the bluff land habitats of the Upper Mississippi River Valley (UMRV). Conservation of C. horridus in this geographic region not only preserves the ecosystem's biodiversity and ecological balance, but also assures the continued study of their biomedically important venoms/toxins. Field studies of C. horridus biology and natural history performed from 1985 to 2015 in southeastern Minnesota and western Wisconsin along the Mississippi River showed populations have declined. Consequently, the implementation of improved conservation measures afforded the species protective status in both states. Historically, accounts of Timber Rattlesnake bites in the UMRV have been sparse, and medical consequences of envenomation have had limited documentation. However, in recent decades cases of envenomation by C. horridus have continued to occur. Retrospective analysis of clinical toxinology consultations documented from 1982 to 2020 on cases of envenomation by C. horridus in the UMRV revealed a very low incidence of bites annually and revealed that their venom can induce a rapid and precipitous decline in platelets.

Neurotoxic respiratory failure absent following Arizona rattlesnake bites

Warnings of neurotoxic respiratory paralysis following envenomation by rattlesnakes (Crotalus sp.) have been included in numerous scholarly publications over the past 60 years, resulting in fear and anxiety in the public and among clinicians. We examine the validity of the widespread belief that rattlesnakes in the arid southwestern United States, and particularly the Mohave Rattlesnake (Crotalus scutulatus), pose a significant risk of medically relevant respiratory weakness and paralysis in humans. A retrospective review of 3440 suspected rattlesnake bites reported to the Arizona Poison and Drug Information Center between 1999 and 2020 produced no evidence of respiratory weakness in a region with three species known to express significant amounts of neurotoxin in their venoms: Crotalus concolor, C. tigris, and the more widely distributed C. scutulatus. A literature review produced numerous warnings regarding respiratory paralysis following envenomation by rattlesnakes in our region that either lacked references or cited sources that did not contain strong supportive data. We found no case reports of neurotoxic respiratory weakness following Arizona rattlesnake bites in the literature and such reports in surrounding states were scant. We conclude that neurotoxic respiratory failure in this region following rattlesnake envenomation is extraordinarily rare. All rattlesnake bites should receive the same consideration and critical care, and warnings about significant risk of respiratory failure are unwarranted, regardless of species involved.

Treatment of a rattlesnake bite on the finger using alternative antivenom management and reconstructive surgery: a case report

Snake bite may be observed from localized symptoms to systemic complications. In most cases, the symptoms as well as the lab course improved by conservative treatment. Therefore, it is recommended that enough of the antivenom be administered initially, and the hospital should be aware of the most common envenomations to obtain the most needed antivenoms. A case of 22-year-old woman bitten on her finger by a Estern Diamondback Rattlesnake. In Korea, there is no antivenom for rattlesnake, so freeze-dried Agkistrodon halys Antivenom was used alternatively. After 10 days of the injury, laboratory finding was almost normalized. At that time, the digit had undergone massive skin necrosis. The wound achieved total healing at postoperative 2 months after flap coverage. This case of rattlesnake bite, which was first described in Korea, present a management with antivenom to other family of snake, and successful surgical treatment.

Fashionably late: A characterization of late coagulopathies in rattlesnake envenomations between Fab and F(ab’)2 antivenoms

BackgroundRattlesnake envenomation may lead to a multitude of clinical effects, including a late onset hemorrhage. Laboratory values such as platelets and fibrinogen are commonly used to assess the risk of developing a life-threatening bleed. To date, no specific threshold has been identified that links a lab value to the risk of bleeding. This has led to widespread practice variability among clinicians managing snake bites. In assessing risk for patients, we apply the concept that the more abnormal the lab values are, the higher the risk probably is. Late onset coagulopathies pose a unique clinical challenge because they indicate the potential risk for a life-threatening hemorrhage, yet they have been identified after hospital discharge. There are currently two antivenom (AV) products on the US market to treat rattlesnake envenomations, a Fab product, CroFab® (BTG, UK) and a F (ab’)2 product, Anavip® (Bioclon, Mexico). ObjectiveThis study intended to characterize the incidence and severity of late coagulopathies reported to a Regional Poison Center (RPC) and hypothesized that late coagulopathies occur at rates higher than previously reported in the literature. Additionally, we sought to compare rates of late coagulopathy between Fab and F (ab’)2 AV. MethodsThe investigators performed an in-depth review of all suspected snakebite envenomations from 2018 to 2020 that presented to an Arizona healthcare facility in the RPC's catchment area between January 2018 through December of 2020. Patients were excluded from analysis if they did not receive any antivenom, had an incomplete medical record with the APDIC, were diagnosed as something other than a rattlesnake bite or had a known medical history that clouded the diagnosis or assessment of a rattlesnake envenomation. ResultsIn total, 522 records were reviewed of which 283 patients met the inclusion criteria. There were 149 patients who received Fab AV and 134 who received F (ab’)2. No significant baseline or demographic differences existed between the groups. 95 of the 283 patients developed a late onset coagulopathy. 39% of the late onset coagulopathies were delayed, 32% were recurrent and 29% were persistent. When comparing the two different AV products, delayed or recurrent coagulopathies occurred in 36% of Fab AV- and 10% of F (ab’)2 treated patients. Persistent coagulopathies occurred in 17% of Fab AV- and 8% of F (ab’)2 treated patients. Interestingly, there were zero cases of late hypofibrinogenemia in any of the 134 F (ab’)2 treated patients compared to 26% of all Fab treated ones. The average onset of late coagulopathy post-bite was 8 days for Fab AV and 7 for F (ab’)2. ConclusionThe results from this study suggest the total rate of late onset coagulopathies may be underestimated. Additionally, our results suggest the potential that F (ab’)2 AV may be associated with fewer late onset coagulopathies, especially late onset hypofibrinogenemia.

Coagulopathy following Crotaliπae snakebites in northeast Florida.

Effects of Crotalinae envenomation vary by geographical areas and research into coagulopathy and effects of antivenom are needed to optimize management. This was a single-center retrospective review with testing on presentation and 4 h after; antivenom administration was noted and data analyzed overall and comparing envenomations. One hundred and nineteen snakebites evaluated with 59 identified as Crotalinae and half receiving antivenom. PT/aPTT was elevated in 20% of water moccasin/copperhead and 21% of rattlesnake bites. DIC-like syndrome occurred in 8% water moccasin/copperhead and 6% rattlesnake bites. Antivenom did not seem to correct PT or aPTT at 4 h follow-up in most cases. Thrombotic microangiopathy was not seen. Coagulopathy was prevalent affecting one in five patients in this cohort and does seem to persist at short interval follow-up, even in those receiving antivenom. We support guidelines recommending clinical monitoring and serial coagulation profiles in such cases. Blood Coagul Fibrinolysis 30:000 - 000 Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

In cold blood: Observational descriptive review of Eastern Massasauga rattlesnake bites reported to a single poison center over time

The Eastern Massasauga rattlesnake (Sistrurus catenatus catenatus) is a pit viper indigenous to the Great Lakes region and the only venomous snake native to Michigan. It is small-to-medium, thick-bodied with dark brown, bow-tie shaped blotches. Its behavior is described as reclusive and docile and it prefers damp habitats. The venom of the Eastern Massasauga is primarily cytotoxic and hemotoxic. Previous literature describes severe coagulopathies following Eastern Massasauga envenomings, with some resulting in death. The objective of this study was to characterize Eastern Massasauga envenomings in humans reported to the Michigan Poison & Drug Information Center from 2003 to 2020, including a description of clinical manifestations, incidence and characterization of coagulopathies, and medical outcome severities. This was a retrospective review of Eastern Massasauga snakebites reported to our state poison center over time. Coagulopathies were classified according to previous toxicological snakebite literature. The degree of envenoming was scored using an institutional guideline, representing a modified version of validated snakebite severity score system. Our longitudinal review demonstrated Eastern Massasauga bites led to clinically significant toxicity, including persistent, recurrent, and late coagulopathies, though with low incidence of bleeding events. Cases typically resolved with use of antivenom. This, to our knowledge, is the largest descriptive case series characterizing Eastern Massasauga snakebites.

The Natural History of a Pygmy Rattlesnake Bite.

Although snake bites are fairly common in the United States, with more than 60,000 occurring each year, venomous snake bites are comparatively rare, with only approximately 7000 per year (1,2). Sistrurus miliarius, or the pygmy rattlesnake, is a venomous snake endemic to the southeastern United States (3,4). A majority of pygmy rattlesnake bites are dry and do not require antivenom (3). This article documents the progression of a pygmy rattlesnake bite of the finger with envenomation, which was not treated with antivenom.

Rattlesnake envenomation in 2 Visayan warty pigs.

Rattlesnake envenomation is an important cause of morbidity and mortality in humans and animals in the southwestern United States and elsewhere. Two Visayan warty pigs (Sus cebifrons) from a regional zoo were submitted for autopsy after being found dead close to a southern Pacific rattlesnake (Crotalus helleri) in their enclosure. Both pigs had severe regionally extensive cutaneous, subcutaneous, and muscle hemorrhage and edema with myonecrosis. Additionally, both pigs had lesions consistent with puncture wounds within the oral cavity, and one pig had a similar wound on a forelimb. The history, and gross and histologic findings, were consistent with envenomation by rattlesnake bite. There are few documented cases of snakebite envenomation in pigs, and it had been suggested that pigs may have some degree of resistance to envenomation. Our results indicate that warty pigs are susceptible to the action of rattlesnake venom.

ONLINE TRAINING ON THE INTRODUCTION AND HANDLING OF THE THREAT OF RATTLESNAKES DURING THE COVID-19 PANDEMIC

Snakes are cold-blooded reptiles that are often found from the lowlands, headlands, soil, trees, freshwater, brackish water, to seawater, except in areas with low temperatures such as the poles. Rattlesnake bites continue to occur anytime and anywhere. Although, currently, there is a covid-19 pandemic in Indonesia. The community needs to know and identify some basic knowledge about snakes. This training was held on April 22, 2020. The method used in this training was demonstration and question and answered through the chat column on Instagram and YouTube accounts for 1 hour. The results of this online training provide additional information and knowledge to the broader community. Also, the number of participants who took part was more significant and scattered throughout Indonesia. Snakes with high venom have a pair of fangs in the upper jaw, and not all highly venomous snakes have triangular heads, such as Bungarus candidus (weling) and Bungarus fasciatus (welang).

Wilderness Cardiology: A Case of Envenomation-Associated Cardiotoxicity Following a Rattlesnake Bite.

Cardiac injury is infrequently described as a complication of snake bite envenomation. We present the case of a 62-year-old male with shortness of breath, right lower extremity edema, and elevated cardiac troponin 6 days after a Northern Pacific rattlesnake bite.

Hematologic Effects Following Crotalinae and Unknown Snake Bites in Northeast Florida

Background: Approximately 5000 snake bites are reported in the United States (US) annually with half of these patients being admitted. Crotalinae species are the most numerous; coral and imported exotic snakes cause a smaller number. Snake venoms are highly stable chemically complex mixtures of proteins. Quantity and composition vary with species and geographic location. Although enzymes contribute to the deleterious effects of the venom, the lethal components may be the smaller low molecular-weight polypeptides. Crotalinae envenomation is known to contain thrombin-like glycoproteins that can induce coagulopathy ranging from asymptomatic lab abnormality to disseminated intravascular coagulopathy (DIC) and life-threatening hemorrhage. In certain geographical areas of the United States thrombocytopenia, hypofibrinogenemia and coagulopathy are common hematological abnormalities, and ones that dictate both a reason for treatment with antivenom as well as an important monitor of therapeutic efficacy. Data on hematological abnormalities following envenomation by crotaline species in Northeast Florida/Southwest Georgia has not been reported before. Methods: We conducted a retrospective review of envenomations that presented to the University of Florida at Jacksonville from April 2013 to October 2018. Patients had to be 16 years or older without any pre-existing hematologic disorder or use of anticoagulant medications. Data including Complete Blood Count, Prothrombin Time (PT), activated Partial Thromboplastin Time (aPTT) and Fibrinogen were measured on presentation, and 4 hours after. Crotaline Fab antivenom (CroFab®) administration was noted if done. Adverse events associated with antivenom therapy, recurrence phenomena, delayed onset of symptoms, and performance of fasciotomy were also recorded. Results: Overall, 119 snakebites were evaluated. The majority were identified as Crotalinae - 25 water moccasin, copperhead or cottonmouth (Agkistrodon piscivorus, Agkistrodon contortrix) bites and 34 rattlesnake (Sistrurus miliarius, Crotalus adamanteus) bites. Male sex dominated the sample with most patients middle-aged (Table 1). More than 80% of patients arrived within 6 hours following the bite. Over 60% of patients received crotaline Fab antivenom. Results are presented in Table 2. Around 12% of patients with water moccasin, copperhead or cottonmouth (Agkistrodon piscivorus, Agkistrodon contortrix) bites had coagulopathy on admission. This compares similarly to data from South Carolina previously showing a 10.89% rate following copperhead bites (Qureshi et al. Blood 2010;116(21):4753). The rate of coagulopathy with rattlesnake bites was however much higher in North Florida at 20.6% - compared to 5.26% in the South Carolina series. Rates of DIC or severe hemorrhage were 8% for water moccasin, copperhead or cottonmouth (Agkistrodon piscivorus, Agkistrodon contortrix) bites and 5.9% for rattlesnake (Sistrurus miliarius, Crotalus adamanteus) bites. When hemostatic defects were looked at separately, the most common abnormality induced was PT/aPTT derangement, followed by hypofibrinogenemia and then thrombocytopenia. This pattern was the same as reported in South Carolina. Recurrence phenomena was observed after 4 hours in a number of patients, however the significance of this remains uncertain as most of these patients remained clinically stable without worsening symptoms. Anaphylactic reaction to the antivenom developed in one patient. Conclusions: In this sample from North Florida, deranged PT/aPTT was the most common hematologic abnormality following envenomation, followed by hypofibrinogenemia and a low rate of thrombocytopenia. Similarities with data from South Carolina were noted, although rattlesnake bites had 4 times higher incidence of coagulopathy in North Florida. DIC or severe hemorrhage was a notable toxicity, affecting 6-8% of Crotalinae cases. Hematologic effects of envenomation do seem to vary by geographic areas in the United States and physicians would benefit from local data to better manage these patients. Disclosures No relevant conflicts of interest to declare.

Envenoming by the rattlesnake Crotalus durissus ruruima in the state of roraima, Brazil.

The aim of this study was to evaluate the clinical-epidemiological factors associated with victims of rattlesnake envenoming in the state of Roraima, Brazil. In this location, rattlesnake accidents are caused by the subspecies Crotalus durissus ruruima. This is a prospective observational study carried out at the General Hospital of Roraima from april 2017 until july 2018. A total of 37 alleged rattlesnake victims had their medical records evaluated. However only one of them proved to be by C. d. ruruima. All individuals were residents from the savannas (lavrados) of Roraima. The town of Bonfim on the border between Brazil and Guyana had the highest occurrence of rattlesnake bites. The most affected group were males aged 13–20 years and farmers. The highest number of incidents occurred during daytime and lower limbs (feet) were the most major affected part of the body. Tourniquets were used as first aid after snake envenoming in 32.4% of victims. Out of 37 patients, 16.2% were classified as severe cases of snakebite envenoming and in 5.4% dry bites seem to have occurred. Among the symptomatic patients, 100% presented local manifestations and 70.3% presented systemic manifestations. The clinical setting showed local effects such as pain and edema while the systemic effects were blurred vision, myalgias, myasthenic facies, palpebral ptosis, muscle weakness and headache. Laboratory results of aspartate aminotransferase (62.2%), creatine phosphokinase (51.3%), lactic dehydrogenase (37.8%), urea level (32.4%) and serum creatinine (29.7%) were increased significantly in relation to the reference standards. In 16.2% of the cases, the victims presented acute kidney injury. Patients were treated with anticrotalic serum in 70.3% of the cases and antibotropic + anticrotalic serum in 24.3%. The victims of C. d. ruruima in Roraima showed a local symptomatology similar to Bothrops envenoming, while systemic symptoms and laboratory analysis proved kidney and muscular injuries, similar to envenoming by Crotalus d. terrificus in Brazil.

353 Point-of-Care Ultrasound in the Evaluation of Rattlesnake Envenomation

To our knowledge, no prior studies investigated the role of point-of-care ultrasound (POCUS) in the evaluation of rattlesnake envenomation. The objective of this study was to determine the utility of POCUS in the management of rattlesnake envenomation in the emergency department (ED). This was a retrospective review of patients presenting to an academic ED with rattlesnake bite and received a POCUS examination after initial clinical assessment. Proximal progression of symptoms and signs in the affected extremity was monitored clinically and repeat POCUS examinations of the extremity were performed. POCUS findings were collected from ED POCUS database. Medical records were then reviewed for history, physical examination findings, laboratory results, additional diagnostic testing, and disposition. The proportion of patients whose treatment plan was altered by the addition of POCUS findings was determined. A total of 21 patients (mean age 48 years ± 15 (SD); 14 males, 7 females) were included in this study. All patients presented with pain, swelling and tenderness at the site of bite (16-lower extremity, 5-upper extremity). On initial POCUS examination, all patients except one case were noted to have subcutaneous edema at the location of snake bite. Twelve patients were also noted to have cobblestoning on initial POCUS. Myokymia was visualized on initial POCUS in 2 patients. On repeat assessments, POCUS demonstrated subcutaneous edema and cobblestoning more proximally than what was determined and marked by treating emergency physicians in 16 patients. Four patients received additional doses of antivenom based on POCUS findings. The one patient who did not have any sonographic findings on initial POCUS was eventually determined to have dry bite by the toxicologist. Patients with myokymia had a complicated hospital course with thrombocytopenia and deterioration of hemodynamic status. Despite limited numbers, our study suggests that POCUS can be a useful adjunct in the evaluation of patients with rattlesnake bite. Ultrasound appears to be more sensitive than clinical assessment in detecting proximal progression of effects of venom and can potentially guide management. Our ongoing prospective study will further define the role of POCUS in the treatment of rattlesnake envenomation.

Comparison of F(ab')2 and Fab antivenoms in rattlesnake envenomation: First year's post-marketing experience with F(ab’)2 in New Mexico

Two antivenoms are available for rattlesnake envenomations in the U.S., Fab (CroFab®, BTG, UK), and F(ab’)2 (Anavip®, Bioclon, Mexico) antivenom (AV) with F(ab’)2AV released in October 2018. The F(ab’)2AV Phase 3 comparative clinical trial demonstrated similar efficacy in treating venom-caused hematologic toxicity, similar rates of Types I and III hypersensitivity reactions, and a lower rate of recurrent hematological effects than FabAV. We hypothesized that a post-marketing, comparative study of effectiveness and rates of hypersensitivity reactions in treating rattlesnake envenomations in New Mexico would demonstrate similar outcomes.Patients eligible for the study presented to a New Mexico healthcare facility between May and October 2019 and were known/suspected to have a rattlesnake bite. Exclusion criteria for antivenom comparison were those with a dry bite, lost to follow-up, or late presentation. All cases were included for patient/bite demographics, initial local control, hematological control, number of maintenance/control doses, development of persistent, recurrent or late-, new-onset hematologic effects, and hypersensitivity reactions. We used Fisher's exact tests for analysis and 0.05 cutoff to determine significance.There were 54 rattlesnake-bitten patients in New Mexico with 17 excluded for comparison of antivenom because of dry bites, loss to follow-up, and one case of late presentation. Thirty-seven patients remained for comparative analysis between F(ab’)2AV (n = 11) and FabAV (n = 26). There were no significant demographic differences between F(ab’)2 and Fab-treated patients. No patient had a Type I hypersensitivity reaction. No rescue doses were given. The rate of recurrent, persistent or late-, new-onset of hematologic effects was 0% with F(ab’)2AV and 29% with FabAV. No patient was readmitted. No patient had bleeding complications. Type III hypersensitivity reactions were similar between F(ab’)2AV (36%) and FabAV (25%).The results of our study are consistent with the Phase 3 clinical comparative trial and indicate no significant differences in safety or effectiveness between FabAV and F(ab’)2AV. F(ab’)2AV offers the advantages of not requiring maintenance doses and may have a lower rate of late hematologic effects in treating rattlesnake envenomations.